Skip to main content

Bruker Licenses IP from Erasmus Medical Center

NEW YORK (GenomeWeb News) – Bruker today announced it has licensed intellectual property from the Erasmus Medical Center for the rapid testing of beta-lactamase activity using MALDI-TOF technology.

The method being licensed is compatible with the Bruker MALDI Biotyper system, which uses MALDI-TOF mass spectrometry for identifying microorganisms, the company said.

Extended-spectrum beta-lactamase is a mechanism of antibiotic resistance, in which enzymes produced by bacteria attack and cleave the beta-lactam ring in antibiotics. MALDI-TOF MS can provide an exact determination of the molecular weight of a broad range of antibiotics, Bruker said, and its MALDI Biotyper can measure the molecular weights of antibiotics which have been converted into fragments in the presence of extended-spectrum beta-lactamase.

The instrument, Bruker added, can provide shorter time-to-result and potentially better specificity than with traditional biochemical testing.

"While MALDI Biotyper-based microbial identification is already established in many countries, we see significant growth potential in MALDI-based beta-lactamase testing," Wolfgang Pusch, executive vice president of the microbiology business at Bruker Daltonics, said in a statement. "The exclusively licensed IP from Erasmus Medical Center further strengthens our own broad portfolio of intellectual property in the field of mass spectrometry-based microbial analysis ranging from sample preparation, data processing, MALDI-TOF technology, direct analysis from positive blood cultures and beta-lactamase testing, and offers laboratories worldwide another tool in the fight against resistant bacteria."

Financial and other terms of the deal were not disclosed.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.